Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4621 (RIG-I Agonist) +/- Pembrolizumab in Advanced Solid Tumors
NCT03739138Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 4
01
Overview
Phase 1, open-label trial of MK-4621 in solid tumor (advanced stage) (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Experiencing Dose Limiting Toxicities, Number of Participants Experiencing Adverse Events and 1 more. Started Dec 2018; status: terminated.
02
Drugs
MK-4621
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03739138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739138.